التفاصيل البيبلوغرافية
| العنوان: |
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study. |
| المؤلفون: |
Comeaux, Christy A, Bart, Stephan, Bastian, Arangassery Rosemary, Klyashtornyy, Vladislav, Paepe, Els De, Omoruyi, Edmund, van der Fits, Leslie, Heesbeen, Roy van, Heijnen, Esther, Callendret, Benoit, Sadoff, Jerald |
| المصدر: |
Journal of Infectious Diseases; 1/15/2024, Vol. 229 Issue 1, p19-29, 11p |
| مصطلحات موضوعية: |
IMMUNE response, COMBINED vaccines, RESPIRATORY syncytial virus, CLINICAL trial registries, CHIMERIC proteins |
| مستخلص: |
Background Ad26.RSV.preF is an adenovirus serotype 26 vector–based respiratory syncytial virus (RSV) vaccine encoding a prefusion conformation-stabilized RSV fusion protein (preF) that demonstrated robust humoral and cellular immunogenicity and showed promising efficacy in a human challenge study in younger adults. Addition of recombinant RSV preF protein might enhance RSV-specific humoral immune responses, especially in older populations. Methods This randomized, double-blind, placebo-controlled, phase 1/2a study compared the safety and immunogenicity of Ad26.RSV.preF alone and varying doses of Ad26.RSV.preF–RSV preF protein combinations in adults aged ≥60 years. This report includes data from cohort 1 (initial safety, n = 64) and cohort 2 (regimen selection, n = 288). Primary immunogenicity and safety analyses were performed 28 days postvaccination (cohort 2) for regimen selection. Results All vaccine regimens were well tolerated, with similar reactogenicity profiles among them. Combination regimens induced greater humoral immune responses (virus-neutralizing and preF-specific binding antibodies) and similar cellular ones (RSV-F–specific T cells) as compared with Ad26.RSV.preF alone. Vaccine-induced immune responses remained above baseline up to 1.5 years postvaccination. Conclusions All Ad26.RSV.preF–based regimens were well tolerated. A combination regimen comprising Ad26.RSV.preF, which elicits strong humoral and cellular responses, and RSV preF protein, which increases humoral responses, was selected for further development. Clinical Trials Registration. NCT03502707. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder